2.13

9.36% -0.22

After Hours: 2.19 0.06 +2.82%

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $2.13, with a volume of 7.26M. It is down -9.36% in the last 24 hours and up +217.44% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$2.35

Open:

$2.23

24h Volume:

7.26M

Relative Volume:

2.42

Market Cap:

$119.09M

Revenue:

$76.19M

Net Income/Loss:

$-1.61M

P/E Ratio:

213.00

EPS:

0.01

Net Cash Flow:

$28.98M

1W Performance:

+205.16%

1M Performance:

+217.44%

6M Performance:

+86.84%

1Y Performance:

+50.00%

1-Day Range:

$2.10

$2.34

1-Week Range:

$0.6562

$2.48

52-Week Range:

$0.5052

$2.48

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2025-03-19

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	2.13	39.03M	76.19M	-1.61M	28.98M	0.01
ONC Beone Medicines Ltd Adr	246.68	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	447.09	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.30	40.37M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	605.39	64.44B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	77.49	6.19B	0	-153.72M	-103.81M	-2.00

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

May 29, 2025

Spero Therapeutics Stock (SPRO) Rockets 225% on Clinical Trial Data - The Globe and Mail

May 29, 2025

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone - Insider Monkey

May 29, 2025

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal - TradingView

May 29, 2025

Spero Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

May 29, 2025

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr - The Pharma Letter

May 29, 2025

May 28, 2025

Biotech Finds Mid-Week Success After Meeting Primary Endpoint - The Globe and Mail

May 28, 2025

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data - insights.citeline.com

May 28, 2025

Spero Therapeutics (SPRO) Stock Explodes: Shares Skyrocket Over 200% in Stunning Midday Rally! - Daily Chhattisgarh News

May 28, 2025

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga

May 28, 2025

GSK, Spero stop UTI drug trial after early success - Reuters

May 28, 2025

GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled By Stocktwits - Investing.com India

May 28, 2025

Spero Therapeutics (SPRO) Soars 255% on Phase 3 Success - GuruFocus

May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results By Investing.com - Investing.com South Africa

May 28, 2025

Spero Therapeutics stock soars on positive phase 3 trial results - Investing.com Australia

May 28, 2025

Spero Therapeutics’ Phase 3 Trial Meets Primary Endpoint - TipRanks

May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study - GlobeNewswire

May 28, 2025

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee | SPRO Stock News - GuruFocus

May 28, 2025

Breakthrough UTI Treatment Success: First-Ever Oral Carbapenem Shows Early Phase 3 Win in $6B Market - Stock Titan

May 28, 2025

May 17, 2025

Analyzing Perrigo (NYSE:PRGO) & Spero Therapeutics (NASDAQ:SPRO) - Defense World

May 17, 2025

May 15, 2025